Regulatory
Sep 07, 2026 · 1 min read · 19,202 views
Novo offers low-dose CagriSema data as approval decision looms
N
Noah Patel
Editorial · Sep 07, 2026
As its capital markets day in London continued on Monday, Novo released data that suggested its investigational metabolic drug CagriSema was competitive with Eli Lilly's Mounjaro when each was given at a
← Previous
Novo aims to diversify with new pipeline assets and bolt-on deals
Next →
In a changed world for cystic fibrosis, a family's fight reveals a new gap in care
